Influence of body mass index on the efficacy of revascularization in patients with coronary artery disease  by Turer, Aslan T. et al.
A
C
DInfluence of body mass index on the efficacy of revascularization in
patients with coronary artery disease
Aslan T. Turer, MD,a Kenneth W. Mahaffey, MD,a,b Emily Honeycutt, MBI,b Robert H. Tuttle, MSPH,b Linda K. Shaw, MS,b
Michael H. Sketch, Jr, MD,a Peter K. Smith, MD,c Robert M. Califf, MD,a and John H. Alexander, MD, MHSa,b
Objective:We examined the effect of body mass index on the association between revascularization strategy and
survival in patients with coronary artery disease.
Methods: Using the Duke Database for Cardiovascular Disease, we selected 22,877 patients who underwent
cardiac catheterization from January 1986 to August 2004 and were found to have significant coronary artery
disease. Patients were categorized into three coronary disease management groups: no revascularization, percu-
taneous coronary intervention, and coronary artery bypass surgery. Propensity scoring was used to control for
coronary artery revascularization strategy. The relationship between body mass index, coronary disease treat-
ment, and survival was assessed via Cox multivariable models adjusting for baseline demographic, clinical,
and angiographic characteristics.
Results: The median body mass index was 27.2 kg/m2 (24.4–30.4) in the overall cohort, 27.1 kg/m2 (24.1–30.3)
in the no revacularization group, 27.4 kg/m2 (24.8–30.9) in the percutaneous intervention group, and 26.9 kg/m2
(24.4–30.1) in the coronary bypass group. Body mass index was a significant, but weak, predictor of revascular-
ization, with higher indexes predicting lower rates of coronary bypass. Thirty-day survival did not differ across
body mass indexes among treatment groups, but survival curves appeared to separate over longer-term follow-up.
An inverted U-shaped survival function was noted across all time points after 30 days, with the lowest risk of
death at a body mass index of approximately 26 kg/m2 (independent of revascularization strategy). Coronary by-
pass was associated with the highest survival at all later time points, whereas no revascularization was associated
with the lowest.
Conclusions: Extremes of body mass index are associated with lower long-term survival in patients with signif-
icant coronary disease. Revascularization, particularly with coronary bypass, is consistently associated with the
best survival across the spectrum of body mass indexes.
Acquired Cardiovascular Disease Turer et alThe incidence of obesity is increasing rapidly in the devel-
oped world, and especially in the United States, where recent
estimates of prevalence are over 30% in adults.1 These re-
ports are of great concern from a public health standpoint,
given the clear association between high body mass index
(BMI) and the risk of death.2-6 Furthermore, this relationship
does not appear to be linear; instead, the slope of the line in-
creases at BMI over 25, signifying particularly high risk for
obese and morbidly obese patients. This negative prognosis
is especially true when evaluating cardiovascular mortality
outcomes, where relative risks are doubled or even tripled.4,7
There has been considerable interest in this problem, but
studies to date have been limited by small sample sizes, short
duration of follow-up, or methodologic problems, such as
arbitrary BMI grouping and failure to account for different
coronary artery disease (CAD) treatments. The published
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doi:10.1016/j.jtcvs.2008.11.0471468 The Journal of Thoracic and Cardiovascular Surdata were reviewed in a recent overview that concluded
that total and cardiovascular mortality was highest in obese
and underweight patients with CAD, confirming the ‘‘obe-
sity paradox.’’8 However, the authors were unable to model
BMI as a continuous variable because of considerable
heterogeneity between cohorts and a lack of patient-level
data. Furthermore, no conclusions could be drawn on the rel-
ative benefits of one method of CAD management over an-
other for any given BMI. The major outstanding question in
clinical practice is whether, given the clear relationship be-
tween BMI and outcome, patients and physicians should
be altering their revascularization decisions on the basis of
the patient’s BMI. We used the Duke Databank for Cardio-
vascular Disease (DDCD) to assess the impact of BMI on the
effect of revascularization on survival in patients with signif-
icant CAD undergoing coronary angiography.
PATIENTS AND METHODS
Patient Population
This study was approved by the Duke University Institutional Review
Board. The population comprised patients undergoing left heart catheteriza-
tion at Duke University Medical Center between January 1, 1986, and Au-
gust 31, 2004. Only patients with significant or severe CAD were included
in the analysis. Patients were excluded if they had moderate or severe val-
vular disease, pericardial or congenital heart disease, shock (defined as sys-
tolic blood pressure < 80 mm Hg or shock as an indication forgery c June 2009
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DAbbreviations and Acronyms
BMI ¼ body mass index
CABG ¼ coronary artery bypass grafting
CAD ¼ coronary artery disease
DDCD ¼ Duke Databank for Cardiovascular
Disease
MI ¼ myocardial infarction
PCI ¼ percutaneous coronary intervention
catheterization), or had previous coronary artery bypass grafting (CABG)
surgery. In addition, patients were also excluded if their BMI was less
than 18.5 (1 patient) or more than 70 kg/m2 (12 patients).
Patients were categorized into one of the following three initial revascu-
larization strategy groups on the basis of therapy within 30 days of baseline
cardiac catheterization: (1) percutaneous coronary intervention (PCI), if
they had PCI; (2) CABG, if they had CABG not preceded by PCI; or (3)
no revascularization (NONE), if they did not have revascularization. To
minimize potential misclassification of patients who had received prior
PCI to the NONE group, we also excluded patients if they had PCI before
their baseline catheterization at our center. Patients who died within 5 days
of initial catheterization (the median interval between catheterization and
CABG at Duke UniversityMedical Center during the study) without receiv-
ing PCI or CABG were excluded from NONE. For patients undergoing re-
vascularization, the follow-up was started at the time of the procedure. Once
patients were assigned to a revascularization group, all outcome events re-
mained associated with that group, regardless of whether the patient subse-
quently had revascularization.Data Collection
Baseline patient characteristics, medical histories, and physical examina-
tions were collected prospectively before cardiac catheterization and entered
into the DDCD.9 Angiographic information was summarized to categorize
patients into CAD severity groups. Catheterization data were used to define
significant CAD as at least one luminal stenosis of 75% or more and severe
CAD to be either significant 3-vessel disease or a left main stenosis of 75%
or more.
Patients were contacted at 6 months and 1 year and annually thereafter as
part of the DDCD follow-up protocol for collection of vital status, rehospi-
talization information, subsequent cardiac procedures, and myocardial
infarction (MI). Nonresponders to these questionnaires and/or telephone
contacts were followed up through the National Death Index for vital status.
Deaths were confirmed by an independent mortality committee. As of July
6, 2005, more than 99% of patients had follow-up. Alive patients were
censored at the time of last follow-up.
Statistical Analysis
Baseline characteristics are categorized into the three revascularization
strategy groups and are reported as percentages for discrete variables and
as medians with 25th and 75th percentiles for continuous variables.
Unadjusted survival results were examined using Kaplan–Meier methods.
Survival estimates were generated using Cox proportional hazards regres-
sion models.
Baseline variables that were clinically relevant or statistically significant
univariable predictors of outcome were selected as candidates for the pro-
pensity and final multivariable model. Candidate variables included age,
sex, white race, BMI, year of catheterization, systolic and diastolic blood
pressure, heart rate, ejection fraction, CAD severity (number of diseased
vessels), hypertension, hyperlipidemia, history of heart failure, diabetes
mellitus, history of chronic obstructive pulmonary disease, history of cere-
brovascular disease, history of MI, history of peripheral vascular disease,TABLE 1. Baseline characteristics by revascularization strategy
Variable Overall (n ¼ 22,877) NONE (n ¼ 7882) PCI (n ¼ 7737) CABG (n ¼ 7258)
Median age, y (IQR) 62 (53–70) 63 (54–70) 59 (50–67) 64 (56–71)
Male sex,% 68.9 66.4 67.9 72.8
White race,% 82.4 79.2 81.7 86.5
BMI, kg/m2, median (IQR) 27.2 (24.4–30.4) 27.1 (24.1–30.3) 27.4 (24.8–30.9) 26.9(24.4–30.1)
History of MI,% 55.5 52.9 63.0 50.3
Hypertension,% 57.5 60.7 53.3 58.4
Diabetes,% 26.1 29.4 21.6 27.2
Hyperlipidemia,% 45.2 41.9 45.7 48.3
History of smoking,% 64.1 64.1 65.4 62.8
History of cerebrovascular disease,% 9.5 11.9 6.3 10.2
History of peripheral vascular disease,% 10.7 13.5 6.4 12.2
History of moderate or severe renal disease,% 2.4 3.2 1.9 2.0
Congestive heart failure,% 17.2 25.5 9.7 16.2
Cath for acute MI,% 27.4 17.5 43.4 21.0
Recent MI (6 wk),% 42.9 35.1 57.1 36.2
Ejection fraction,%, median (IQR) 54 (43–62) 51 (39–61) 56 (47–63) 53 (43–62)
No. of diseased vessels,%
1 39.2 48.2 59.4 8.0
2 29.3 27.4 31.3 29.1
3 31.5 24.4 9.4 62.9
Extent of CAD,%
Significant (not severe) 67.0 75.0 90.2 33.7
Severe 33.0 25.0 9.8 66.3
BMI, Body mass index; CABG, coronary artery bypass grafting; CAD, coronary artery disease; IQR, interquartile range; MI, myocardial infarction; NONE, no revascularization;
PCI, percutaneous coronary intervention. All P< .001, except for smoking (P ¼ .003).
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DFIGURE 1. BMI distribution of the study population. BMI, Body mass index.family history of CAD, history of liver disease, history of moderate or se-
vere kidney disease, connective tissue disease, history of dementia, history
of metastatic cancer, history of any tumor, history of peptic ulcer, mitral in-
sufficiency, New York Heart Association Class, MI within prior 6 weeks,
third heart sound, carotid bruits, acute MI, mild valvular disease, history
of smoking, left main disease of 50% or more, elective catheterization,
and urgent catheterization.
Logistic regression analysis was used to determine the probability of the
physician’s and patient’s propensity to choose a specific revascularization
strategy. Three propensity scores—(1) CABG versus NONE, (2) CABG
versus PCI, and (3) PCI versus NONE—were created for each patient,
which, taken as a whole, represent that patient’s probability of selection
for each strategy relative to another. Propensity scores were included in
the final models.
For the final multivariable models, variables were chosen using stepwise
selection with a P value of .05 as the level of statistical significance.
Interactions of revascularization strategy with CAD severity, BMI with
CAD severity, and BMI with revascularization strategy were tested for sig-
nificance.10 Splines were used to generate curves comparing survival across
BMI.11 All analyses were performed with SAS software version 8.2
(SAS Institute Inc, Cary, NC).
RESULTS
The analysis included 22,877 patients with significant or
severe CAD. The median duration of follow-up was 7 years
(interquartile range 3.1–11.9 years). Approximately 65% of
the patients in the cohort were either followed up for over 10
years or had died within 10 years of follow-up.1470 The Journal of Thoracic and Cardiovascular SuThe baseline characteristics stratified by revascularization
strategy are shown in Table 1. The median BMI was 27.2 kg/
m2 (24.4–30.4 kg/m2) in the overall cohort, 27.1 kg/m2
(24.1–30.3 kg/m2) in the NONE group, 27.4 kg/m2 (24.8–
30.9 kg/m2) in the PCI group, and 26.9 kg/m2 (24.4–30.1
kg/m2) in the CABG group. The BMI distribution of the en-
tire study population is shown in Figure 1. When examined
by revascularization strategy, there were no major differ-
ences in the distribution of BMIs.
Table 2 shows unadjusted survivals. The adjusted sur-
vivals of the study population stratified by revascularization
strategy are shown in Figure 2. CABG was associated with
higher adjusted survival than the other treatment modalities
TABLE 2. Unadjusted survivals by revascularization strategy
Time NONE PCI CABG
30 d 97% 98% 97%
6 mo 93% 97% 95%
1 y 90% 96% 94%
5 y 70% 87% 82%
10 y 51% 73% 62%
15 y 36% 53% 42%
CABG, Coronary artery bypass grafting; NONE, no revascularization; PCI, percutane-
ous coronary intervention.rgery c June 2009
Turer et al Acquired Cardiovascular DiseaseFIGURE 2. Adjusted survival for all patients stratified by revascularization strategy. CAD, Coronary artery disease; CABG, coronary artery bypass graft;
PCI, percutaneous coronary intervention.A
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Dafter 12 months, and this benefit appeared to be consistent
over the duration of follow–up. Table 3 shows the predictors
of revascularization strategy based on the results of the logis-
tic regression propensity models. BMI was a significant vari-
able in each of the propensity scores, although its relative
contribution to the overall probability of undergoing a partic-
ular procedure was small compared with other clinical vari-
ables. The majority of patients were treated with a single
revascularization strategy. Crossover rates were 11.9% for
NONE to PCI, 13.8% for CABG to PCI, 21% for NONE
to CABG, and 21% for PCI to CABG. The median time
to crossover from NONE to CABG was 3 years and from
PCI to CABG, 1.5 years.
Survival estimates for the different revascularization strat-
egy groups at 30 days, 1 year, and 10 years are provided in
Figure 3. There was no significant difference in survival at
30 days among revascularization strategy groups or across
BMI. At longer follow-up, the survival curves continued
to diverge, with CABG being associated with the highest
survival across the entire spectrum of BMI. NONE was con-
sistently associated with the lowest long–term survival. This
relationship was similar when analyzed for procedures per-
formed in the early balloon angioplasty (1986–1990), late
balloon angioplasty (1991–1995), and stent (1996–2004)
eras (data not shown). The BMI inflection point of these sur-
vival curves was at a BMI of approximately 26 kg/m2 and
was independent of revascularization strategy (interaction
P value ¼ .12).
Among the entire cohort, there were 711 (3.1%) patients
with morbid obesity (BMI  40). Of these, 32.3% were
treated with NONE, 43.2% with PCI, and 24.5% received
CABG. The revascularization rate was not different in pa-The Journal of Thoracic and Ctients with BMIs of 40 or more compared with those with
BMIs less than 40 (67.7 vs 65.5%; P¼.245); however, there
was less use of CABG (24.5 vs 32.0%; P< .0001). Among
patients with severe (ie, left main or 3-vessel) CAD, there
was a trend toward a lower rate of CABG in morbidly obese
patients compared with those not morbidly obese (55.3 vs
61.5%; P ¼ .072).
DISCUSSION
Although there is a clear and previously described excess
risk associated with extremes of BMI, the association be-
tween revascularization strategy and better outcome appears
to be independent of BMI in this large cohort of patients with
CAD undergoing coronary angiography. Importantly, revas-
cularization (especially with CABG) is associated with
a higher rate of survival even at the extremes of BMI.
Prior work has described a similar U-shaped relationship
between BMI and the risk of overall and cardiovascular
death.4,8 Our data support these findings of an ‘‘obesity par-
adox’’; however, this is the first analysis to include the im-
pact of treatment strategy in such a way as to allow
a direct comparison of outcomes between patients treated
with revascularization strategies for any given BMI.
At one extreme, very low BMI has been associated with
overall mortality, possibly through a confounding effect
by unrecognized or unmeasured comorbidities.4,8 At the
other extreme, obesity continues to attract attention as its
prevalence increases. It is clearly linked to several major car-
diovascular risk factors but is also increasingly recognized
as an independent contributor both to the development of
CAD and to cardiovascular death.8,12-14 The results of this
analysis show that BMI influences the risk of death evenardiovascular Surgery c Volume 137, Number 6 1471
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DTABLE 3. Major predictors of each revascularization strategy from
the propensity model
Variable Wald c2 OR 95% CI
A. PCI vs NONE: Probability of undergoing PCI
Year of catheterization* 679.9
1986–1993 1.201 1.181 1.222
1997–2004 1.097 1.070 1.125
Ejection fraction (per 1% increase) 256.9 1.037 1.032 1.041
Acute MI 165.8 2.226 1.970 2.514
Left main disease  50% 140.4 0.384 0.328 0.450
MI within prior 6 wk 103.3 2.097 1.818 2.418
No. of diseased vessels 102.8 0.769 0.731 0.809
NYHA class (classes I–III vs class IV) 94.1 0.645 0.591 0.705
Elective catheterization 70.8 0.677 0.618 0.741
History of MI 48.6 0.635 0.559 0.721
White race 32.3 1.317 1.198 1.448
Age (per 10-y increase) 31.8 0.908 0.878 0.939
History of peripheral vascular disease 27.9 0.707 0.622 0.804
History of cerebrovascular disease 20.6 0.737 0.646 0.841
Mild valvular disease 14.3 0.522 0.373 0.731
BMI (below 26, or per 1 kg/m2 increase) 11.4 1.038 1.016 1.061
Hyperlipidemia 10.4 1.131 1.050 1.219
Diabetes mellitus 10.3 0.868 0.796 0.946
B. CABG vs NONE: Probability of undergoing CABG
No. of diseased vessels 2643.7 4.126 3.909 4.355
Left main disease  50% 245.7 2.282 2.059 2.530
Ejection fraction 222.2 1.047 1.041 1.054
Age (OR per 10 y) 164.4
Below 67 y 1.115 1.055 1.178
Above 67 y 0.513 0.462 0.568
Elective catheterization 113.3 0.624 0.572 0.680
White race 98.7 1.721 1.546 1.915
Year of catheterization* 76.5 1.039 1.030 1.048
NYHA class 72.6 0.841 0.808 0.875
History of cerebrovascular disease 30.2 0.704 0.621 0.798
Diabetes mellitus 29.2 0.779 0.712 0.853
History of MI 27.6 0.734 0.654 0.824
Mild valvular disease 23.7 0.469 0.346 0.636
Hyperlipidemia 23.1 1.215 1.122 1.315
History of peripheral vascular disease 21.7 0.757 0.673 0.851
Hypertension 14.8 0.851 0.784 0.924
History of moderate or severe renal
disease
14.1 0.622 0.486 0.797
BMI 13.9
Below 26 1.030 1.006 1.056
Above 26 0.982 0.972 0.992
History of connective tissue disease 10.1 0.389 0.217 0.697
C. CABG vs PCI: Probability of undergoing CABG
No. of diseased vessels 3264.0 6.330 5.941 6.743
Left main disease  50% 525.9 6.283 5.370 7.352
Year of catheterization* 164.3
1986–1993 0.890 0.871 0.909
1997–2004 0.960 0.933 0.989
Acute MI 101.8 0.450 0.386 0.526
MI within 6 wk before catheterization 41.1 0.648 0.568 0.740
Ejection fraction (below 60, or per 1%
increase)
32.4 0.987 0.983 0.9921472 The Journal of Thoracic and Cardiovascular Surafter revascularization and medical therapy for CAD, and,
furthermore, that it affects prognosis independently of revas-
cularization strategy.
The precise reason for the excess risk associated with obe-
sity is unclear, but a number of biological mechanisms have
been postulated, including effects on vascular remodeling15
and endothelial function,16 associated low-level chronic in-
flammation,17 impaired ventricular function,18 left ventricu-
lar hypertrophy,19 and QT prolongation.20 Confounding
from low cardiorespiratory fitness, itself probably a signifi-
cant predictor of adverse cardiovascular outcomes, may
also, in part, explain the influence of BMI on prognosis.21-23
Finally, biases and barriers may exist in access to medical
care for the obese and especially the morbidly obese patient,
which may contribute negatively to outcomes.24 The results
of propensity modeling suggest that BMI does influence the
likelihood of coronary revascularization and, perhaps more
important, the mode of revascularization selected. This idea
of a potential treatment bias is further supported by the find-
ing that, even among patients with traditionally ‘‘surgical’’
disease (namely, left main or 3-vessel disease), rates of
CABG were lower in those patients who were morbidly
obese.
It is commonly believed that obese patients may not be ap-
propriate surgical candidates because of an increased risk of
complications25-36 and higher mortality after CABG. There
are data, including from this analysis, to support the finding
that obese patients undergoing CABG have worse outcomes
than nonobese patients,8,31,35-39 although a number of previ-
ous studies conversely have not found higher mortality with
CABG in obese25-30,32-34,40-45 and severely obese pa-
tients.25,28,32,40,41,44,46 All of these studies, however, have
failed to account for the outcomes of similar patients treated
with PCI or without revascularization. Although obese pa-
tients treated with CABG may have worse outcomes than
lighter-weight patients, their outcomes are better with
CABG than with alternative revascularization strategies or
medical therapy.
Several limitations of our study must be acknowledged.
First, this is a single-center study and may not reflect the
experiences of other institutions. For example, the high
TABLE 3. Continued
Variable Wald c2 OR 95% CI
Age (or per 10 y) 29.3
Below 70 y 1.143 1.083 1.206
Above 70 y 0.699 0.591 0.826
BMI 14.3 0.984 0.975 0.992
White race 13.4 1.260 1.113 1.427
BMI, Body mass index; CABG, coronary artery bypass grafting; CI, confidence inter-
val;MI,myocardial infarction; NYHA,New York Heart Association; NONE, no revas-
cularization; OR, odds ratio; PCI, percutaneous coronary intervention. *Odds ratio for
year of catheterization refers to the yearly increase in odds of receiving one treatment
over another; for PCI vs. NONE and CABG vs. PCI, the OR from 1994–1996 did not
increase and was the same as 1993. Only Wald c2 values over 10 are shown.gery c June 2009
Turer et al Acquired Cardiovascular DiseaseFIGURE 3. Survival across the spectrum of BMI by treatment group at short-, intermediate-, and long-term follow-up. CABG, Coronary artery bypass graft-
ing; PCI, percutaneous coronary intervention.A
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Drate of smoking in our population may reflect local social
factors. Second, the DDCD includes patients enrolled
over approximately 20 years. Although this provides for
a large population and a long duration of follow-up, there
have been therapeutic advancements in the treatment of
CAD from both a medical and revascularization stand-
point, and findings from the past may be less relevant to
the future. The DDCD does not contain longitudinal infor-
mation on medication use, so we cannot account for the ad-
equacy of medical therapy with any revascularization
strategy. As with any observational analysis, there may
be measured or unmeasured confounders that are associ-
ated with either revascularization strategy or outcome. Pa-
tients with acute MI were more likely to have PCI and
those with multivessel disease were more likely to receive
CABG. We performed propensity analysis to adjust for the
likelihood of receiving a particular treatment and to miti-
gate the effects of measurable confounders. There may
also be unmeasured confounders, such as socioeconomic
and psychologicl factors, which are not collected and
thus cannot be adjusted for. Although observational data-
bases have limitations, because patients of extremes of
BMI are often excluded from randomized clinical trials,
large observational datasets have an important role to
play in understanding the influence of BMI on outcome
in real world clinical practice. Finally, we did not assess
the impact of revascularization beyond 30 days—such as
repeat revascularization, crossover from medical to revas-
cularization, or weight loss. Only a minority of the popula-
tion crossed over, and there are considerable analytic
challenges in accounting for crossover, in modeling time-The Journal of Thoracic and Cto-crossover, and introducing bias from patients dying be-
fore crossover.
In conclusion, although extremes of BMI are associated
with worse survival in patients with CAD undergoing angi-
ography, revascularization (particularly with CABG) is as-
sociated with better outcomes across all BMIs. Obese
patients with significant CAD amenable to surgical revascu-
larization should be considered for CABG.
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